SR ONE CAPITAL PARTNERS I, LP
Insider CIK 1853724 · ACLX 10% owner · DSGN 10% owner · EFTR 10% owner
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| EFTR eFFECTOR Therapeutics, Inc | S Sale | 2023-11-27 | 2023-11-29 | 178,585 | $0.61 | $108.9K | 1,821,415 | SEC↗ |
| EFTR eFFECTOR Therapeutics, Inc | S Sale | 2023-11-27 | 2023-11-29 | 430,578 | $0.61 | $262.7K | 4,391,536 | SEC↗ |
| ACLX Arcellx, Inc. | S Sale | 2023-05-11 | 2023-05-15 | 631,932 | $45.00 | $28.44M | 2,834,879 | SEC↗ |
| ACLX Arcellx, Inc. | S Sale | 2023-05-11 | 2023-05-15 | 6,485 | $46.15 | $299.3K | 2,828,394 | SEC↗ |
| ACLX Arcellx, Inc. | S Sale | 2023-05-11 | 2023-05-15 | 3,804 | $46.15 | $175.6K | 1,658,780 | SEC↗ |
| ACLX Arcellx, Inc. | S Sale | 2023-05-11 | 2023-05-15 | 370,612 | $45.00 | $16.68M | 1,662,584 | SEC↗ |
| DSGN Design Therapeutics, Inc. | P Buy | 2022-12-20 | 2022-12-20 | 40,000 | $8.14 | $325.6K | 6,526,476 | SEC↗ |
| DSGN Design Therapeutics, Inc. | P Buy | 2022-12-19 | 2022-12-20 | 360,000 | $8.63 | $3.11M | 6,486,476 | SEC↗ |
| DSGN Design Therapeutics, Inc. | P Buy | 2022-12-16 | 2022-12-20 | 500,000 | $8.28 | $4.14M | 6,126,476 | SEC↗ |
| ACLX Arcellx, Inc. | C Conversion deriv | 2022-02-08 | 2022-02-10 | 649,795 | — | $0 | 0 | SEC↗ |
| ACLX Arcellx, Inc. | C Conversion deriv | 2022-02-08 | 2022-02-10 | 533,389 | — | $0 | 0 | SEC↗ |
| ACLX Arcellx, Inc. | C Conversion deriv | 2022-02-08 | 2022-02-10 | 433,196 | — | $0 | 0 | SEC↗ |
| ACLX Arcellx, Inc. | C Conversion deriv | 2022-02-08 | 2022-02-10 | 1,550,309 | — | $0 | 0 | SEC↗ |
| ACLX Arcellx, Inc. | C Conversion deriv | 2022-02-08 | 2022-02-10 | 666,651 | — | $0 | 0 | SEC↗ |
| ACLX Arcellx, Inc. | C Conversion | 2022-02-08 | 2022-02-10 | 666,651 | — | $0 | 2,216,960 | SEC↗ |
| ACLX Arcellx, Inc. | C Conversion | 2022-02-08 | 2022-02-10 | 433,196 | — | $0 | 433,196 | SEC↗ |
| ACLX Arcellx, Inc. | P Buy | 2022-02-08 | 2022-02-10 | 66,667 | $15.00 | $1.00M | 3,466,811 | SEC↗ |
| ACLX Arcellx, Inc. | C Conversion | 2022-02-08 | 2022-02-10 | 649,795 | — | $0 | 3,400,144 | SEC↗ |
| ACLX Arcellx, Inc. | P Buy | 2022-02-08 | 2022-02-10 | 1,600,000 | $15.00 | $24.00M | 2,033,196 | SEC↗ |
| ACLX Arcellx, Inc. | C Conversion | 2022-02-08 | 2022-02-10 | 1,550,309 | — | $0 | 1,550,309 | SEC↗ |
| ACLX Arcellx, Inc. | C Conversion | 2022-02-08 | 2022-02-10 | 533,389 | — | $0 | 2,750,349 | SEC↗ |
| DSGN Design Therapeutics, Inc. | C Conversion deriv | 2021-03-30 | 2021-04-01 | 7,236,938 | — | $0 | 0 | SEC↗ |
| DSGN Design Therapeutics, Inc. | C Conversion deriv | 2021-03-30 | 2021-04-01 | 1,526,718 | — | $0 | 0 | SEC↗ |
| DSGN Design Therapeutics, Inc. | P Buy | 2021-03-30 | 2021-04-01 | 250,000 | $20.00 | $5.00M | 5,626,476 | SEC↗ |
| DSGN Design Therapeutics, Inc. | C Conversion | 2021-03-30 | 2021-04-01 | 4,439,839 | — | $0 | 4,439,839 | SEC↗ |
| DSGN Design Therapeutics, Inc. | C Conversion | 2021-03-30 | 2021-04-01 | 936,637 | — | $0 | 5,376,476 | SEC↗ |